5-Hydroxytryptophan as adjuvant therapy in treatment of moderate to severe obsessive-compulsive disorder: a double-blind randomized trial with placebo control-Reference-Cited by-同舟云学术

5-Hydroxytryptophan as adjuvant therapy in treatment of moderate to severe obsessive-compulsive disorder: a double-blind randomized trial with placebo control

Published:2020-06-18 Issue:5 Volume:35 Page:254-262
ISSN:0268-1315
Container-title:International Clinical Psychopharmacology
language:en
Short-container-title:

Author:

Yousefzadeh Farzaneh,Sahebolzamani Erfan,Sadri Arash,Mortezaei Amirhosein,Aqamolaei Ali,Mortazavi Seyyed Hosein,Shalbafan Mohammd Reza,Ghaffari Salomeh,Alikhani Rosa,Mousavi Seiedeh Bentolhoda,Naderi Sina,Shamabadi Ahmad,Jalilevand Shakiba,Akhondzadeh Shahin

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Pharmacology (medical),Psychiatry and Mental health

Reference45 articles.

1. Using mice to model obsessive compulsive disorder: from genes to circuits.;Ahmari;Neuroscience,2016

2. Modafinil as a treatment for attention-deficit/hyperactivity disorder in children and adolescents: a double blind, randomized clinical trial.;Amiri;Prog Neuropsychopharmacol Biol Psychiatry,2008

3. L-carnosine as an adjuvant to fluvoxamine in treatment of obsessive compulsive disorder: a randomized double-blind study.;Arabzadeh;Hum Psychopharmacol,2017

4. Serotonin synthesis, release and reuptake in terminals: a mathematical model.;Best;Theor Biol Med Model,2010

5. 5-Hydroxytryptophan: a clinically-effective serotonin precursor.;Birdsall;Altern Med Rev,1998

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pharmakotherapie;S3-Leitlinie Zwangsstörungen;2024

2. Efficacy and safety of 5-hydroxytryptamine-3 (5-HT3) receptor antagonists in augmentation with selective serotonin reuptake inhibitors (SSRIs) in the treatment of moderate to severe obsessive–compulsive disorder: a systematic review and meta-analysis of randomized clinical trials;Scientific Reports;2023-11-27

3. Agomelatine augmentation of sertraline in the treatment of moderate to severe obsessive-compulsive disorder: a randomized double-blinded placebo-controlled clinical trial;BMC Psychiatry;2023-09-21

4. Reboxetine Combination Therapy With Fluoxetine in Moderate to Severe Obsessive-Compulsive Disorder: A Placebo-Controlled, Double-Blind, Randomized Trial;Clinical Neuropharmacology;2023-07-18

5. Untargeted metabolomics analysis in drug-naïve patients with severe obsessive–compulsive disorder;Frontiers in Neuroscience;2023-06-02